Trial Profile
A SINGLE CENTRE, OPEN LABEL, PHASE II CLINICAL STUDY OF THE ADJUNCTIVE BENEFIT OF WF10 TO STANDARD CAPECITABINE CHEMOTHERAPY IN SUBJECTS WITH UNRESECTABLE PANCREATIC CANCER
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2011
Price :
$35
*
At a glance
- Drugs WF 10 (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 21 Oct 2005 New trial record.